Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment.

MLA

Frantellizzi, Viviana, et al. “Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-Resistant Prostate Cancer Patients Candidates to 223RaCl Treatment.” Radiology & Oncology, vol. 54, no. 1, Mar. 2020, pp. 40–47. EBSCOhost, https://doi.org/10.2478/raon-2019-0058.

APA

Frantellizzi, V., Pani, A., Ippoliti, M. D., Farcomeni, A., Aloise, I., Colosi, M., Polito, C., Pani, R., & Vincentis, G. D. (2020). Scintigraphic load of bone disease evaluated by DASciS software as a survival predictor in metastatic castration-resistant prostate cancer patients candidates to 223RaCl treatment. Radiology & Oncology, 54(1), 40–47. https://doi.org/10.2478/raon-2019-0058

Chicago

Frantellizzi, Viviana, Arianna Pani, Maria Dea Ippoliti, Alessio Farcomeni, Irvin Aloise, Mirco Colosi, Claudia Polito, Roberto Pani, and Giuseppe De Vincentis. 2020. “Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-Resistant Prostate Cancer Patients Candidates to 223RaCl Treatment.” Radiology & Oncology 54 (1): 40–47. doi:10.2478/raon-2019-0058.